During its latest fiscal year, BD reported its revenues dipping 1.4 percent as it made $19.1 billion in 2021 and raked in $18.9 billion in 2022.
The company attributed part of the loss to less demand for its COVID-19 diagnostic tests. Among its three main segments — medical, life sciences and interventional — BD’s life sciences sales fell 16.3 percent compared to last year’s figures because of dwindling demand for COVID-19 tests.
BD whittled its 2023 projected earnings for the tests to be between $125 million and $175 million — a sharp dropoff from 2022’s sales, which were $511 million.
